Outcome of combination antiviral therapy in chronic hepatitis C virus infection during therapy of acute lymphoblastic leukemia

Saudi Journal of Gastroenterology

Volumn 17, Issue 4, 2011, Pages 283-286

  Ayyub, Muhammad ^a   El Moursy, Soha A ^a   Al Abbas, Fahd ^a  

^a Oncology Center   (Saudi Arabia)

Author keywords

Acute lymphoblastic leukemia; chronic HCV hepatitis; peginterferon 2a

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; DEXAMETHASONE; MERCAPTOPURINE; METHOTREXATE; ORAL ANTIDIABETIC AGENT; PEGINTERFERON ALPHA2A; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN; VINCRISTINE; VIRUS RNA;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADD ON THERAPY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CASE REPORT; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DRUG DOSE ESCALATION; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; MAINTENANCE THERAPY; MALE; NEUTROPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

6-MERCAPTOPURINE; ADMINISTRATION, ORAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIVIRAL AGENTS; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2A; MALE; POLYETHYLENE GLYCOLS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RIBAVIRIN; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 79960279815     PISSN: 13193767     EISSN: 19984049     Source Type: Journal    
DOI: 10.4103/1319-3767.82586     Document Type: Article

References (15)

1. Paydas S, Kili B, Sahin B, Budayci R. Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders in Southern Turkey. Br J Cancer 1999;80:1303-5. (Pubitemid 29308596)
2. Ishak K, Baptista A, Bianchi L, Callea F, DeGroote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-9.
3. Dibenedetto SP, Ragusa R, Sciacca A, Di Cataldo A, Miraglia V, D'Amico S, et al. Incidence and morbidity of infection by hepatitis C virus in children with acute lymphoblastic leukaemia. Eur J Pediatr 1994;153:271-5. (Pubitemid 24101352)
4. Campello C, Poli A, Dal MG, Besozzi-Valentini F. Seroprevalence, viremia and genotype distribution of hepatitis C virus: A community-based population study in northern Italy. Infection 2002;30:7-12. (Pubitemid 34146405)
5. Schllkopf C, Smedby KE, Hjalgrim H, Rostgaard K, Panum I, Vinner L, et al. Hepatitis C infection and risk of malignant lymphoma. Int J Cancer 2008;122:1885-90. (Pubitemid 351413439)
6. Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001;34:809-16. (Pubitemid 32928008)
7. Ribas A, Butturini A, Locasciulli A, Aric M, Gale RP. How important is hepatitis C virus (HCV)-infection in persons with acute leukemia? Leuk Res 1997;21:785-8. (Pubitemid 27458631)
8. Herrine SK, Rossi S, Navarro VJ. Management of patients with chronic hepatitis C infection. Clin Exp Med 2006;6:20-6.
9. Danish FA, Koul SS, Subhani FR, Rabbani AE, Yasmin S. Role of hematopoietic growth factors as adjuncts in the treatment of chronic hepatitis C patients. Saudi J Gastroenterol 2008;14:151-7.
10. Dibenedetto SP, Ragusa R, Sciacca A, Di Cataldo A, Miraglia V, D'Amico S, et al. Incidence and morbidity of infection by hepatitis C virus in children with acute lymphoblastic leukaemia. Eur J Pediatr 1994;153:271-5. (Pubitemid 24101352)
11. Berg T, Von Wagner M, Nasser S, Sarrazin C, Heintges T, Buggisch P, et al. Extended treatment duration for hepatitis C virus type 1: Comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterol 2006;130:1086-97
12. Muretto P, Tomassoni S, Staccioli MP, Tabellini L, D'Adamo F, Delfini C. Does interferon-a exert an anti-leukemic effect by enhancing cell mediated immunity in chronic myeloid leukemia? Haematologica 2000;85:212-3. (Pubitemid 30366670)
13. H Komatsu, T Fujisawa, A Inui, Y Miyakawa, M Onoue, I Sekine, et al. Efficacy of interferon in treating chronic hepatitis C in children with a history of acute leukemia. Blood 1996;87:4072-5. (Pubitemid 26152250)
14. Waldron P. Interferon treatment of chronic active hepatitis C during therapy of acute lymphoblastic leukemia. Am J Hematol 1999;61:130-4. (Pubitemid 29252391)
15. Lackner H, Moser A, Deutsch J, Kessler HH, Benesch M, Kerbl R, et al. Interferon-alpha and ribavirin in treating children and young adults with chronic hepatitis C after malignancy. Pediatrics 2000;106:E53.